Panel Proposes Standards for Reporting Data From Immuno-Oncology Trials

Published: Wednesday, Mar 06, 2019
Michael A. Postow, MD
Michael A. Postow, MD
The standards for reporting findings from immunotherapy studies should reflect the unique efficacy and toxicity characteristics of this rapidily emerging modality, with detailed and transparent explanations of definitions, according to a panel of experts.

The recommendations were developed starting in 2016 by a working group of members of ASCO and SITC that included medical oncologists, clinical researchers, biostatisticians, and immunologists, as well as government and industry members. The 12 recommendations are grouped under efficacy data, toxicity information, or details about combination therapies. The recommendations are listed here verbatim as bullet points.

Standards for Efficacy Reporting

• Report the criteria used to evaluate response to therapy and the rationale for the selected criteria
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x